Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

BTK antibody (pThr602)

This Rabbit Polyclonal antibody specifically detects BTK in WB and ELISA. It exhibits reactivity toward Human, Mouse, Monkey and Pig.
Catalog No. ABIN2746343

Quick Overview for BTK antibody (pThr602) (ABIN2746343)

Target

See all BTK Antibodies
BTK (Bruton Agammaglobulinemia tyrosine Kinase (BTK))

Reactivity

  • 130
  • 80
  • 65
  • 11
  • 5
  • 4
  • 2
  • 1
Human, Mouse, Monkey, Pig

Host

  • 152
  • 15
Rabbit

Clonality

  • 135
  • 33
Polyclonal

Conjugate

  • 79
  • 12
  • 9
  • 6
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
This BTK antibody is un-conjugated

Application

  • 116
  • 60
  • 49
  • 40
  • 40
  • 23
  • 21
  • 19
  • 18
  • 16
  • 10
  • 3
  • 2
  • 2
  • 1
Western Blotting (WB), ELISA
  • Binding Specificity

    • 36
    • 16
    • 15
    • 15
    • 9
    • 8
    • 7
    • 7
    • 5
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 550-650, pThr602

    Cross-Reactivity

    Mouse (Murine), Monkey, Pig (Porcine)

    Cross-Reactivity (Details)

    The antibody does not cross react to any other cellular protein

    Characteristics

    Phospho specific BTK-selective antibodies were generated against a peptide taken from the human BTK protein spanning AA from 544-561. The BTK-selective antibodies are affinity purified on an immobilized antigen based affinity matrix, the isolated antibodies were then stabilized in antibody stabilization buffer for long-term storage. The anti-BTK-selective antibodies are fully characterized for applications in western blotting and ELISA at the recommended dilutions. The Supplier provides BTK Western blot positive control samples in SDS-PAGE sample buffer.

    Purification

    Affinity Purified

    Immunogen

    Synthetic peptide corresponding to unique amino acid sequence on human BTK protein between 550-650 with Phosphorylated Threonine 602

    Isotype

    IgG
  • Application Notes

    Antibodies were tested in ELISA and western blotting applications at 1:500 dilution using ABIN1686581 samples. Antibody dilutions for these antibodies are for reference only, investigators are expected to determine the optimal conditions. Application of this antibody in other protocols has not yet tested.
    WB: > 1:500
    IMM & IP pull-down assays: n.d.
    IHC: n.d.
    Investigators using this antibody in protocols other than listed above can request a complimentary sample of this antibody. n.d. not necessarily means the antibody is not suitable for that application, it simply means we have not yet characterized the antibody for that application.
    The antibody labels a strong band of PBTK at79 kDa in ABIN1686581 samples and in severalcancer cell lines.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Concentration

    0.6 μg/μL

    Storage

    -20 °C

    Storage Comment

    Storage of very dilute antibody solutions is not recommended.
  • Target

    BTK (Bruton Agammaglobulinemia tyrosine Kinase (BTK))

    Alternative Name

    BTK

    Background

    Bruton tyrosine kinase (BTK) is a member of the Tec family kinases with a well-characterized role in BCR-signaling and B-cell activation. BTK is activated upstream by Src-family kinases Blk, Lyn, and Fyn, and Btk in turn phosphorylates and activates phospholipase-Cγ (PLCγ), leading to Ca2+ mobilization and activation of NF-κB and MAP kinase pathways. Mutations in BTK gene in humans give rise to X-linked agammaglobulinemia, an inherited disorder that is characterized by severe B cell-specific defects including severely decreased levels of immunoglobulin production and the absence of B cells, suggesting the importance and selectivity of BTK to B cells. Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases. The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling since mutations disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway. Several lines of evidence suggest that the BCR pathway may provide a survival signal in tumor cells in non-Hodgkin lymphoma (NHL). BTK was recently identified as an essential signaling kinase for survival of a subtype of diffuse large B-cell lymphoma. Thus, small molecule BTK inhibitors may provide therapeutic benefit in the treatment of lymphoma and autoimmune diseases.

    NCBI Accession

    NP_000052

    UniProt

    Q06187

    Pathways

    Fc-epsilon Receptor Signaling Pathway, Hormone Transport, Activation of Innate immune Response, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Toll-Like Receptors Cascades, BCR Signaling
You are here:
Chat with us!